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Tumor markerObjectives: Protein induced by vitamin K absence or antagonist-II (PIVKA-II) has been used as a tumormark-
er to aid in the diagnosis of hepatocellular carcinoma (HCC). We developed an anti-PIVKA-II monoclonal anti-
body, 3C10, and a fully automated quantitative immunoassay for PIVKA-II on the ARCHITECT® i-systems. The
aim of this study was to characterize the epitope of 3C10 and to evaluate the reactivity to PIVKA-II of this assay.
Methods: The epitope characterization was examined by using prothrombin γ-carboxyglutamic acid resi-
dues (Gla) domain polypeptides which are amino acid residues 17–27 that include four Gla residues at positions
19, 20, 25 and 26. The correlation with Picolumi PIVKA-II MONO (Eidia, Tokyo, Japan) and tube type equivalency
was evaluated by using the developed fully automated quantitative immunoassay.
Results: Peptides having glutamic acid residues (Glu) at Gla domains strongly reacted to 3C10 but lost reac-
tivitywhen theGlu at positions 19 or 20was changed toGla. The results were equivalentwith an existing in vitro
diagnostics product for PIVKA-II using theMU-3 antibody. A correlation studywith the Picolumi PIVKA-II MONO
gave a correlation coefﬁcient of 0.99 and a regression slope of 0.92. No difference between a plain serum tube and
a rapid serum tube including thrombin (RST) was observed on ARCHITECT PIVKA-II.
Conclusions: The results demonstrate that this anti-PIVKA-II antibody detects equivalent epitopes withMU-
3 and has equivalent reactivity to PIVKA-II as MU-3. Moreover, the ARCHITECT PIVKA-II assay has good
correlation with the existing PIVKA-II product, and is applicable for use with RST.
© 2015 The Authors. The Canadian Society of Clinical Chemists. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Liver cancer is the seventh most common cancer and the second
cause of death from cancer worldwide. The incidence rate andmortality
rate were 10.1 and 9.5 per 100,000 persons in 2012, respectively [1].
Hepatocellular carcinoma (HCC) is themajor histologic type among pri-
mary liver cancers occurring worldwide, accounting for 70% to 85% of
the total burden [2]. HCC can be treated by resection, liver transplanta-
tion, or local ablation with radiofrequency for patients diagnosed at an
early stage [3]. However, although alpha-fetoprotein (AFP) is the most
commonly used tumor marker for HCC, its clinical diagnostic accuracy
is unsatisfactory due to low sensitivity and speciﬁcity [4]. Therefore,
there is an urgent need for developing better HCC-speciﬁc biomarkers.
Several serological biomarkers have been suggested as other potential
biomarkers for early detection of HCC. Protein induced by vitamin K ab-
sence or antagonist-II (PIVKA-II), also known as des-gamma-carboxy
prothrombin (DCP), is a useful marker for the diagnosis of HCC, andnt, Abbott Japan Co., Ltd., 278
kawa).
ty of Clinical Chemists. Publishedthe combined measurement of PIVKA-II and AFP is superior to AFP
alone [4,5].
Prothrombin, a blood coagulation protein synthesized in the liver, is
converted to an active form after the 10 glutamic acid residues (Glu) in
theγ-carboxyglutamic acid (Gla) domain at positions 6, 7, 14, 16, 19, 20,
25, 26, 29 and 32 are γ-carboxylated to Gla by vitamin-K dependent γ-
glutamyl carboxylase. In patients with HCC, γ-carboxylation of pro-
thrombin is impaired so that PIVKA-II is formed instead of prothrombin
[6]. Liebman et al. [7] ﬁrst reported that the serum PIVKA-II concentra-
tionwas signiﬁcantly higher in patientswithHCC by radioimmunoassay
using a polyclonal antibody. They puriﬁed PIVKA-II from ascites ﬂuid of
patientswithHCC and analyzed its Gla content [8]. Then,Motohara et al.
[9,10] made the MU-3 monoclonal antibody against PIVKA-II and
established an assay system with higher sensitivity. Clinical studies
have demonstrated that the assay system using MU-3 antibody shows
high sensitivity and speciﬁcity to PIVKA-II in patients with HCC [11].
PIVKA-II has been used as an aid for diagnosis of HCC in Japan.
Sugo et al. [12] reported that the reactivity of MU-3 antibody in-
creased when the number of Gla was less than ﬁve per molecule.
Furthermore, Naraki et al. [13] described the epitope of PIVKA-II
reacting to MU-3 antibody. The epitope of MU-3 antibody was located
within the amino acid residues 17–27 in the Gla domain. They reportedby Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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PIVKA-II variants preferentially synthesized in HCC patients have less
than four Gla whereas PIVKA-II variants in benign liver diseases have
more than ﬁve Gla [13].We developed themonoclonal antibody against
PIVKA-II, 3C10, and established a fully automated quantitative immuno-
assay for PIVKA-II. The aim of this study was to characterize the epitope
of 3C10 and to evaluate the reactivity to PIVKA-II of this assay.2. Materials and methods
2.1. Preparation of 3C10 antibody
The 3C10hybridomacell linewas prepared by immunization ofmice
with the synthesized PIVKA-II peptide 13–27 described by Yoshimura
et al. [14]. Puriﬁcation of 3C10 antibodywas performed by using Protein
G Sepharose 4 Fast Flow (GE Healthcare Japan, Tokyo, Japan). Analyses
of the puriﬁed 3C10 antibodywere carried out by SDS-PAGE, gel perme-
ation chromatography (GPC), and Western blotting.2.2. Preparation of PIVKA-II antigen
Human prothrombin (Enzyme Research Laboratories, South Bend,
IN, USA)was dialyzed against 0.1M ammoniumacetate solution and ly-
ophilized. After the lyophilization, the prothrombin was heated for 8 h
at 105 °C for decarboxylation [15]. The decarboxylated prothrombin
was puriﬁed by a 3C10 coated afﬁnity column and a Superdex 200 col-
umn (GE Healthcare Japan, Tokyo, Japan). Analysis of the PIVKA-II anti-
gen was carried out by GPC.2.3. Assay principal of the automated chemiluminescent immunoassay for
PIVKA-II on ARCHITECT
The ARCHITECT PIVKA-II assay is a two-step sandwich immunoas-
say, using chemiluminescent paramagnetic microparticle technology
for quantitative determination of PIVKA-II. The ARCHITECT PIVKA-II
assay utilizes microparticles coated with 3C10 antibody which recog-
nizes an epitope in PIVKA-II within the Gla domain at the N-terminus
as the solid phase to capture PIVKA-II. The analyte-microparticle com-
plex is detected with an acridinium labeled murine anti-prothrombin
monoclonal antibodyMCA1–8 (Abbott Laboratories, IL, USA) conjugate,
which recognizes an epitope in prothrombin part of the Gla domain
(amino acid 33–46) shown in Fig. 1.Fig. 1. Assay principal of thFollowing a wash step, pre-trigger and trigger solutions are added
to the reaction mixture. The resulting chemiluminescent reaction is
measured as relative light units (RLUs). The RLUs detected by the AR-
CHITECT optical system are related to the amount of PIVKA-II Ag in
the sample.2.4. Gla domain polypeptide
Peptides used for epitope characterization were purchased from
the Toray Research Center (Tokyo, Japan). The purity of all peptides
was conﬁrmed to be more than 95% by high performance liquid
chromatography.2.5. Specimens
The AFP positive sera for the dilution linearity study of the
ARCHITECT PIVKA-II were obtained from ProMedDx, LLC (Norton, MA,
USA). Serum specimens for the correlation of the ARCHITECT PIVKA-II
with Picolumi PIVKA-II MONO were obtained from ProMedDx, LLC
and Bioreclamation IVT (Hicksville, NY, USA). Normal matched speci-
mens from blood collected in a plain serum tube, a serum separator
tube (SST) and a rapid serum tube including thrombin (RST) were ob-
tained from ProMeDx, LLC. All human specimens used for this study
were collected under institutional review board approved protocols.2.6. Evaluation methods
The epitope characterization studies of 3C10 and MU-3 antibodies
were examined with competing peptides against PIVKA-II antigens by
the ARCHITECT PIVKA-II assay and Picolumi PIVKA-II MONO assay, re-
spectively. The ten kinds of peptides prepared at various concentrations
were mixed with 480mAU/mL PIVKA-II, and inhibition by each peptide
wasmeasured by theARCHITECT PIVKA-II and Picolumi PIVKA-IIMONO
assays.
Reactivities of 3C10 to thedecarboxylated prothrombin and to native
PIVKA-II from ﬁve individual serum specimens were tested in the dilu-
tion linearity study of ARCHITECT PIVKA-II assay. The decarboxylated
prothrombin and native PIVKA-II adjusted to 30,000 mAU/mL were di-
luted to 30.03%, 9.02%, 2.71%, 0.81%, 0.24%, 0.07%, and 0.02% with the
ARCHITECT PIVKA-II calibrator diluent and measured by ARCHITECT
PIVKA-II assay. The values of coefﬁcient of determination (R2) for a
linear regression were calculated.e ARCHITECT PIVKA-II.
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MONO across the measuring range was evaluated using 119 serum
specimens from various hepatic diseases including AFP positive pa-
tients, liver cancer, non-alcoholic fatty liver disease, liver cirrhosis, hep-
atitis C, etc. Correlation was analyzed by using the Passing–Bablok
regression method and the Spearman's correlation coefﬁcient.
Sample type equivalencywas evaluatedwith specimens drawn from
5 normal individuals using 3 types of blood collection tubes (plain
serum tube, SST and RST). Both neat samples and samples spiked with
100 mAU/mL of PIVKA-II antigen were assayed by the ARCHITECT
PIVKA-II and Picolumi PIVKA-II MONO assays. The PIVKA-II value of
each sample was compared to the value of the corresponding plain
serum tube sample. Statistical differences versus plain serum tube
were evaluated using the paired t-test.
Data were analyzed using Analyse-It version 2.22 (Analyse-It
Software Ltd., Leeds, UK).
3. Results
3.1. Characterization of the 3C10 antibody epitope
To identify the epitope of the 3C10 and MU-3 antibodies, the inhibi-
tion between PIVKA-II and the competing peptides against PIVKA-II an-
tigens was tested by the ARCHITECT PIVKA-II and Picolumi PIVKA-II
MONO assays. Ten peptides were used to analyze the epitope of 3C10
and MU-3 antibody. The amino acid sequences of the 10 peptides are
shown in Table 1. There are four Gla residues (positions 19, 20, 25 and
26) between amino acid 17 to 27 in the Gla domain.We prepared 8 pos-
sible combinations (peptide-1 to 8) to convert each Gla to Glu in posi-
tions 19, 20 and 25. Furthermore, we prepared 4 possible combinations
(peptide-1, 4, 9 and 10) to convert each Gla to Glu in positions 25 and
26 with Glu in positions 19 and 20.
The inhibition rates by peptide-1 to 8 on ARCHITECT PIVKA-II assay
and Picolumi PIVKA-II MONO assay are shown in Figs. 2A and B.
Peptide-1, where all 4 positions are Glu residues, most strongly
inhibited the binding of 3C10 and MU-3 to PIVKA-II antigen. The half
maximal Inhibitory Concentrations (IC50) to 3C10 and MU-3 byTable 1
Amino acid sequences of the Gla domain and peptides used for epitope determination. Gla
residues are denoted by γ.peptide-1 were 0.84 μM and 0.98 μM, respectively. Peptide-4, with Gla
at position 25, showed slightly lower inhibition to 3C10 and MU-3
than peptide-1. The IC50 to 3C10 and MU-3 by peptide-4 were
3.10 μMand 5.75 μM, respectively. Peptide-2 and 3,with Gla at positions
19 and 20, respectively, weakly inhibited the reaction to 3C10 and MU-
3. Peptides 5, 6, 7, and 8 contain 2 or more Gla residues and did not in-
hibit the reaction to 3C10 andMU-3. The inhibition rates by peptide 1–8
to 3C10were similar with the inhibition toMU-3. These results showed
that at least one Glu at positions 19 or 20 is essential for 3C10 antibody
binding and the further addition Glu at position 25 enhances the 3C10
antibody binding. Moreover, the 3C10 binding afﬁnities to the peptides
were equivalent to the MU-3 binding afﬁnities.
The inhibition rates by peptide-1, 4, 5, 8, 9 and 10 on ARCHITECT
PIVKA-II assay and Picolumi PIVKA-II MONO assay are shown in Figs.
2C and D. Peptide-9 strongly inhibited the reaction to 3C10 and MU-3.
The inhibition rates were equivalent with peptide-1. The IC50 to 3C10
and MU-3 by peptide-9 were 1.10 μM and 1.49 μM, respectively.
Peptide-10 showed slightly lower inhibition to 3C10 and MU-3 than
peptide-9. The inhibition rates were equivalent with peptide-4. The
IC50 to 3C10 and MU-3 by peptide-10 were 4.95 μM and 9.23 μM,
respectively. These results showed that the further addition Glu at posi-
tion 26 has no effect on the 3C10 antibody binding as well as the MU-3
antibody binding.
3.2. Reactivity of 3C10 antibody to decarboxylated prothrombin and to
native PIVKA-II in serum specimens
The dilution linearity study of the ARCHITECT PIVKA-II was exam-
ined by using decarboxylated prothrombin and native PIVKA-II from
ﬁve individual patients. The linearity of this assay is shown in Fig. 3.
The R2 value for a linear regression through the measurement range of
ARCHITECT PIVKA-II assay of the decarboxylated prothrombin was
0.985. The R2 values of native PIVKA-II were from 0.976 to 0.982.
3.3. Correlation between the Picolumi PIVKA-II MONO and the ARCHITECT
PIVKA-II assay
We evaluated the correlation between the ARCHITECT PIVKA-II
assay and the Picolumi PIVKA-II MONO assay (existing PIVKA-II product
in Japan). The result is shown in Fig. 4. The regression slope calculated
using the Passing–Bablok regression method was 0.92. The Spearman's
correlation coefﬁcient was 0.99.
3.4. Evaluation of tube type equivalency between plain serum tube, SST and
RST
We evaluated the value differences by using three types of serum
tubes. The value differences of the neat samples and samples spiked
with 100 mAU/mL of PIVKA-II antigen between plain serum tube and
the two other serum tubes on ARCHITECT PIVKA-II and Picolumi
PIVKA-II MONO assays are shown in Fig. 5. The mean differences of
SST and RST versus plain serum on ARCHITECT PIVKA-II were 1% and
4%, respectively. The mean differences of SST and RST versus plain
serum on Picolumi PIVKA-II MONOwere−4% and−16%, respectively.
The differences of SST and RST versus plain serum on ARCHITECT
PIVKA-II and the difference of SST versus plain serum on Picolumi
PIVKA-II MONO were non-signiﬁcant. However the PIVKA-II level
using RST on Picolumi PIVKA-II MONO was signiﬁcantly lower than
PIVKA-II level using the plain serum tube.
4. Discussion
In this study, we characterized the epitope of 3C10 antibody that
was developed by immunization with the synthesized peptide 13–27
of PIVKA-II. To identify the epitope in Gla domain of PIVKA-II that is de-
tected by 3C10, ten combinations of changes of the four Gla to Glu
Fig. 2. Inhibition of 3C10 andMU-3 antibody reactivity to PIVKA-II by various peptides with residues at positions 19, 20, 25 and 26 having different Gla and Glu. PIVKA-II was mixed with
the peptide 1–8, and the inhibition rate to anti-PIVKA-II antibody by each peptide wasmeasured by ARCHITECT PIVKA-II assay (A) and Picolumi PIVKA-II MONO (B). PIVKA-II was mixed
with the peptide 1, 4, 5, 8, 9 and 10, and the inhibition rate to anti-PIVKA-II antibody by each peptide was measured by ARCHITECT PIVKA-II assay (C) and Picolumi PIVKA-II MONO (D).
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showed that binding to 3C10 was signiﬁcantly decreased when one or
both of the Glu at positions 19 and 20 was changed to Gla. Therefore,
the Glu at positions 19 or 20 are essential for 3C10 antibody binding.
The addition of Glu at position 25 enhanced the 3C10 antibody binding.
The further addition of Glu at position 26 is no effect on the 3C10 anti-
body binding. The inhibition results to 3C10 using ten peptides were
equivalent with those for MU-3. The inhibition results to MU-3 were
similar to the results reported by Naraki et al. [13]. Our results indicate
that the epitope of 3C10 antibody is equivalent to that of the MU-3
antibody.
The 3C10 antibody showed equivalent reactivities to decarboxylated
prothrombin and to native PIVKA-II from the suspected patient with
HCC through the measurement range of ARCHITECT PIVKA-II assay.Fig. 3. Reactivity of 3C10 to the decarboxylated prothrombin and to native PIVKA-II from
ﬁve serum specimens by the dilution linearity study of ARCHITECT PIVKA-II assay. The R2
values of patient-1, 2, 3, 4, 5, and decarboxylated prothrombin were 0.976, 0.979, 0.979,
0.982, 0.982, and 0.985, respectively.These results indicate that the 3C10 antibody binds to native PIVKA-II
in the patient serum equivalent to a decarboxylated prothrombin. We
evaluated the correlation between ARCHITECT PIVKA-II using the
3C10 antibody and Picolumi PIVKA-II MONO using the MU-3 antibody
by using liver diseases specimens including patients with liver cancer.
The slope and correlation coefﬁcient were good. From these results,
the ARCHITECT PIVKA-II assay using 3C10 antibody gave similar detec-
tion of PIVKA-II in clinical specimens to the existing PIVKA-II assaysFig. 4. Correlation between the Picolumi PIVKA-II MONO and the ARCHITECT PIVKA-II
assay.
Fig. 5. Evaluation of tube type equivalency between plain serum tube, SST and RST. The neat samples and spiked samples which were added 100 mAU/mL of PIVKA-II antigen into each
specimenwere assayed by the ARCHITECT PIVKA-II (A) and Picolumi PIVKA-II MONO (B). The PIVKA-II value of each sample was compared to the value of the corresponding plain serum
tube sample. The p-value of the statistical differences versus plain serum was calculated by the paired t-test.
1124 H. Kinukawa et al. / Clinical Biochemistry 48 (2015) 1120–1125using theMU-3 antibody. However, the numbers of tested clinical spec-
imens were limited in this study. A more extensive clinical study of the
ARCHITECT PIVKA-II assay should be performed in the future.
In Japan, the PIVKA-II assay has been commonly used as an aid of di-
agnosis andmonitoring for the patients with HCC. However, some com-
mercial available PIVKA-II assays have limitations to the usage of blood
collection tubes.We performed the tube type study by using three kinds
of serum tubes onARCHITECT PIVKA-II and Picolumi PIVKA-IIMONOas-
says. In these results, no differences between serum tube typeswere ob-
served on the ARCHITECT PIVKA-II assay, whereas the PIVKA-II levels
collected by RST were signiﬁcantly decreased on Picolumi PIVKA-II
MONO assay. Thrombin cleavages in human prothrombin were identi-
ﬁed at Arg51-Thr52/Arg54-Asp55, Arg155-Ser156, and Arg284-Thr285
[16–18]. Petrovan et al. [19] reported that the rate of cleavage at
Arg51-Thr52/Arg54-Asp55, Arg155-Ser156, and Arg284-Thr285 is greatly af-
fected by the presence of calcium ions. In the absence of calcium ions,
thrombin relatively efﬁciently proteolyzes peptide bonds at Arg51-
Thr52/Arg54-Asp55 and Arg155-Ser156. Church et al. [20] reported the
cleavage of prothrombin by thrombin at Arg155-Ser156 is inhibited in
the presence of calcium ions, and the protective effect has been attribut-
ed to conformational changes mediated by calcium ions binding to the
Gla domain. It was reported that the Gla domain in PIVKA-II does not
bind to calcium ions [21]. Thrombin may cleavages the peptide bonds
at Arg51-Thr52/Arg54-Asp55 and Arg155-Ser156 on PIVKA-II. The
ARCHITECT PIVKA-II uses two different antibodies each which can rec-
ognize a peptide in the Gla domain. Therefore, the assay is not signiﬁ-
cantly affected by the PIVKA-II cleavages by proteases. The differences
of PIVKA-II levels collected by RST versus serum plain tube between
ARCHITECT PIVKA-II and Picolumi PIVKA-II MONO might be caused by
the PIVKA-II cleavage by thrombin.
In conclusion, the results demonstrate that the anti-PIVKA-II anti-
body 3C10 has equivalent epitopes and reactivity to PIVKA-II with
MU-3. Moreover, the fully automated ARCHITECT PIVKA-II assay using
3C10 has good correlation with existing PIVKA-II product, and is appli-
cable to a rapid serum tube.Conﬂict of interest
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